Leerink Swann began coverage on shares of Tocagen (NASDAQ:TOCA) in a report released on Monday, The Fly reports. The brokerage issued a market perform rating and a $10.26 target price on the stock.
TOCA has been the subject of a number of other reports. Zacks Investment Research downgraded Tocagen from a buy rating to a hold rating in a research note on Saturday, January 19th. B. Riley started coverage on Tocagen in a research note on Monday, December 31st. They issued a buy rating and a $22.00 target price for the company. Finally, Robert W. Baird started coverage on Tocagen in a research note on Friday, January 18th. They issued an outperform rating and a $20.00 target price for the company. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company has an average rating of Buy and an average price target of $18.58.
Shares of Tocagen stock opened at $9.94 on Monday. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.91 and a quick ratio of 5.91. The stock has a market capitalization of $236.19 million, a P/E ratio of -4.07 and a beta of 3.50. Tocagen has a fifty-two week low of $6.47 and a fifty-two week high of $15.80.
Tocagen (NASDAQ:TOCA) last issued its earnings results on Wednesday, February 27th. The company reported ($0.96) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.35). Tocagen had a negative net margin of 271.43% and a negative return on equity of 92.56%. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. Equities research analysts anticipate that Tocagen will post -2.94 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Stratos Wealth Partners LTD. boosted its position in shares of Tocagen by 9.0% during the fourth quarter. Stratos Wealth Partners LTD. now owns 11,449 shares of the company’s stock worth $94,000 after buying an additional 949 shares during the period. Bank of America Corp DE boosted its position in shares of Tocagen by 28.6% during the fourth quarter. Bank of America Corp DE now owns 14,584 shares of the company’s stock worth $120,000 after buying an additional 3,240 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Tocagen by 7.7% during the fourth quarter. Bank of New York Mellon Corp now owns 56,938 shares of the company’s stock worth $468,000 after buying an additional 4,093 shares during the period. Meeder Asset Management Inc. boosted its position in shares of Tocagen by 162.8% during the fourth quarter. Meeder Asset Management Inc. now owns 9,961 shares of the company’s stock worth $82,000 after buying an additional 6,170 shares during the period. Finally, Stifel Financial Corp boosted its position in shares of Tocagen by 34.0% during the fourth quarter. Stifel Financial Corp now owns 26,392 shares of the company’s stock worth $215,000 after buying an additional 6,698 shares during the period. Institutional investors and hedge funds own 36.88% of the company’s stock.
Tocagen Company Profile
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Further Reading: Special Dividends
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.